News and Press Releases

Fluorous Technologies, Inc. (FTI) announces Successful Presence at the ACS Fall National Meeting

Monday, September 16, 2002
Download this FTI news release (PDF).

On August 18, 2002, Professor Dennis P. Curran, Founder and Chief Scientific Advisor of FTI presented to greater than one thousand delegates on his work entitled "Fluorous Synthesis Techniques: From Separating Mixtures to Making Mixtures". The talk provided an introduction and a broad overview of fluorous chemistry as well as its novel applications in synthetic organic chemistry as applied to drug discovery.

At the science conference, Dr. Wei Zhang and Christine Chen, both researchers at FTI, gave detailed presentations on their ongoing work. Dr. Zhang presented new fluorous reagents and tagging strategies using fluorous chemistry in his talk entitled "Fluorous Synthesis: Using New tagging Strategies for Solution Phase Parallel Synthesis". Other applications of fluorous techniques were presented in two posters titled "Fluorous Mixture Synthesis of Individually Pure Mappicine Analogs" and "New Alternative to Solid Support in Combinatorial Libraries: A Fluorous Version of the Marshall Resin". The latest developments of fluorous tags and diverse applications of these reagents attracted a large crowd during these presentations.

"We are very pleased with the level of interest shown at our presentations and poster shows. This is a great indication that the word is spreading quickly about the time savings delivered through the use of FTI's techniques and FluoroFlash® products," said Kyle Derstine, Director of Marketing at FTI.

Presentation slides can be viewed here.

FTI (www.fluorous.com) is a Pittsburgh-based chemical technology company focused on the life sciences market. For further information please contact us at bizdev@fluorous.com.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including risks relating to the early stage of products under development; uncertainties related to patent protection; dependence on third parties, including strategic partners, collaborators and key personnel; future capital needs; and risks relating to the development and commercialization, if any, of Fluorous Technologies' proposed products (such as marketing, manufacturing, safety, regulatory, patent or product liability, supply, competition and other risks).